118 related articles for article (PubMed ID: 8874202)
1. Inhibitory effect of a CD4-CDR3 peptide analog on graft-versus-host disease across a major histocompatibility complex-haploidentical barrier.
Townsend RM; Briggs C; Marini JC; Murphy GF; Korngold R
Blood; 1996 Oct; 88(8):3038-47. PubMed ID: 8874202
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with a CD4-CDR3 peptide analog and cyclosporin A to prevent graft-vs-host disease in a MHC-haploidentical bone marrow transplantation model.
Townsend RM; Gilbert MJ; Korngold R
Clin Immunol Immunopathol; 1998 Jan; 86(1):115-9. PubMed ID: 9434804
[TBL] [Abstract][Full Text] [Related]
3. A synthetic CD4-CDR3 peptide analog enhances bone marrow engraftment across major histocompatibility barriers.
Koch U; Korngold R
Blood; 1997 Apr; 89(8):2880-90. PubMed ID: 9108408
[TBL] [Abstract][Full Text] [Related]
4. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
Koch U; Choksi S; Marcucci L; Korngold R
J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
[TBL] [Abstract][Full Text] [Related]
5. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
6. A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis.
Marini JC; Jameson BA; Lublin FD; Korngold R
J Immunol; 1996 Oct; 157(8):3706-15. PubMed ID: 8871674
[TBL] [Abstract][Full Text] [Related]
7. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease.
Johnson BD; Truitt RL
Blood; 1995 Jun; 85(11):3302-12. PubMed ID: 7756664
[TBL] [Abstract][Full Text] [Related]
8. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
9. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
Drobyski WR; Majewski D
Blood; 1996 Jun; 87(12):5355-69. PubMed ID: 8652851
[TBL] [Abstract][Full Text] [Related]
10. Prevention of lethal graft-versus-host disease following allogeneic bone marrow transplantation in mice by short course administration of LF 08-0299.
Annat J; Churaqui E; Dutartre P; Bruley-Rosset M
Transplantation; 1996 Sep; 62(6):721-9. PubMed ID: 8824467
[TBL] [Abstract][Full Text] [Related]
11. Role of CD28 in acute graft-versus-host disease.
Yu XZ; Martin PJ; Anasetti C
Blood; 1998 Oct; 92(8):2963-70. PubMed ID: 9763584
[TBL] [Abstract][Full Text] [Related]
12. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Cetkovic-Cvrlje M; Roers BA; Waurzyniak B; Liu XP; Uckun FM
Blood; 2001 Sep; 98(5):1607-13. PubMed ID: 11520814
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
[TBL] [Abstract][Full Text] [Related]
15. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD.
Petrus MJ; Williams JF; Eckhaus MA; Gress RE; Fowler DH
Biol Blood Marrow Transplant; 2000; 6(2A):182-9. PubMed ID: 10816026
[TBL] [Abstract][Full Text] [Related]
16. Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease.
Chen Y; Schlegel PG; Tran N; Thompson D; Zehnder JL; Chao NJ
Blood; 1997 Feb; 89(4):1452-9. PubMed ID: 9028970
[TBL] [Abstract][Full Text] [Related]
17. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
Hsieh MH; Varadi G; Flomenberg N; Korngold R
Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
[TBL] [Abstract][Full Text] [Related]
18. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
[TBL] [Abstract][Full Text] [Related]
19. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
20. A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis.
Okamoto S; Watanabe M; Yamazaki M; Yajima T; Hayashi T; Ishii H; Mukai M; Yamada T; Watanabe N; Jameson BA; Hibi T
Eur J Immunol; 1999 Jan; 29(1):355-66. PubMed ID: 9933118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
